New hope for kids with Hard-to-Treat bleeding disorder

NCT ID NCT06168851

First seen Jan 04, 2026 · Last updated May 12, 2026 · Updated 23 times

Summary

This study tests a new drug (anti-CD38 antibody) in 60 children aged 6 and older with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The drug aims to raise platelet counts safely in kids who haven't improved with standard therapies. Participants receive the drug and are monitored for 8 weeks to see if their platelet levels increase without needing rescue treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TREATMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chinese Academy of Medical Science and Blood Disease Hospital

    RECRUITING

    Tianjin, Tianjin Municipality, 300020, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.